

Press Release: 25th of April 2019

**International Cannabis and Cannabinoids Institute (ICCI) announces
its co-founder, Steph Sherer, as President.**

Through her work as Founder and Executive Director of Americans for Safe Access (ASA), Sherer has made medical cannabis available to patients worldwide. During her time as Executive Director of ASA, Sherer was responsible for the drafting of some of the first distribution laws in the United States and has been a leader in bringing patients to the table with lawmakers. Now she comes to Prague to run the International Institute for Cannabis and Cannabinoids (ICCI).

“For the last 17 years, I have worked to break-down societal and governmental barriers for patients who need access to medical cannabis. Now that these barriers are tumbling down it is important that industry evolves to provide products for these populations that are safe, standardized and targeted and that there is the scientific infrastructure to support these efforts. I am excited to extend my advocacy for access to medical cannabis to include the scientific community, investors, and sectors of the industry that are committed to serving the patient community.” – Steph Sherer, ICCI Co-Founder and President

ICCI was founded as a joint project of patient organizations, scientific societies and American investment company Dioscorides Global Holdings (DGH). The headquarters are located in Prague, and as center of excellence, it cooperates internationally with governments, universities and research institutes as well as companies in the cannabis, hemp, bio-tech, and agricultural sectors.

Sherer co-founded DGH, a private equity firm that invests strategically in medical cannabis, with partner Ben Bronfman. Sherer is the foremost international leader and expert on medical cannabis patient advocacy. In 2002, Sherer founded Americans for Safe Access (ASA) the largest national member-based organization of patients, medical professionals, scientists, and concerned citizens promoting safe and legal access to cannabis for therapeutic use and research. For seventeen years, Sherer's leadership guided the efforts, with lawmakers across the US and globally, to adopt and improve medical cannabis legislation and regulatory policy across the US and its territories as well as representing patients on Capitol Hill. Alongside the American Herbal Products Association (AHPA) and the American Herbal Pharmacia, Sherer co-created the first medical cannabis industry standards in the areas of Distribution, Cultivation, Analytics, and Manufacturing, Packaging, and Labeling.

“We are excited that Steph has decided to focus more on ICCI in this next phase of her career. She has been a strong patient advocate and has a clear vision of the trajectory of the medical cannabis industry.” – Pavel Kubu, ICCI CEO.

“The appointment of Steph Sherer is an important milestone for ICCI. Steph brings her longstanding track record of success in bringing together disparate parties in the cannabis world that have led to major advances in patient access, research potentialities and liberalization of legislation on the local, national and international level. said Ethan Russo MD, ICCI Director of Research and Development. “Her experience and broad knowledge of the field will be well applied to our work going forward on cannabis therapeutics and practical applications of industrial hemp.”

About the ICCI - International Cannabis and Cannabinoids Institute

The International Cannabis and Cannabinoids Institute (ICCI) was established as a joint project of patient organizations, Czech scientific societies and the investment firm Dioscorides Global Holdings. The main headquarters are in Prague, Czech Republic. ICCI cooperates with universities (such as Charles University, the Czech Technical University or the Hebrew University in Jerusalem), hi-tech companies and associations. Furthermore, ICCI identifies, coordinates and supports global research priorities for the advancement of cannabis and cannabinoid treatments through a multidiscipline, evidence-based approach that incorporates innovative tools and methods.

About ASA – Americans for Safe Access

ASA is the largest national organization of patients, medical cannabis providers, medical professionals, scientists and concerned citizens promoting safe and legal access to cannabis for therapeutic use and research with over 100,000 active members in all 50 states (USA). Since its inception, ASA has successfully shifted the national debate around medical cannabis, which has focused solely on the legality and ethics of arresting and prosecuting patients for cannabis use, to include the real concerns of patients, such as access and civil protections. ASA has worked with lawmakers across the country to adopt and improve medical cannabis legislation and regulatory policy as well as representing patients on Capitol Hill.

Media Contact

Jakub Večerka, 603 185 441, jakub.vecerka@icci.science